Malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programs

^{Xavier Mariette, Sandrine Aspeslagh, Richard Moriggl, Vijay Rajendran, Christine Rudolph, Paul Van Hoek, Nadia Verbruggen, Chris Watson, Sven Borchmann, Andreas Stallmach}

Poster Number: 0277

Session Date and Time: 12 November 2022, 
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

Baseline characteristics of and early outcomes in the first 200 patients with RA treated with filgotinib in a prospective observational study

^{James Galloway, Karen Bevers, Patrick Verschueren, Roberto F. Caporali, Susana Romero Yuste, Jérôme Avouac, Emilia Gvozdenovic, Kristina Harris, Monia Zignani, Gerd Burmester}

Poster Number: 0276

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

Exploratory analysis of filgotinib safety data in patients with moderately to severely active RA and an increased risk of cardiovascular events: data from phase 2 and 3 clinical trials

^{Maya H. Buch, Gerd R. Burmester, Xavier Mariette, Christina Charles-Schoeman, Vijay Rajendran, Pieter-Jan Stiers, Agustin Cerani, Paul Van Hoek, Katrien Van Beneden, Yoshiya Tanaka, Hendrik Schulze-Koops, René Westhovens, Ennio Giulio Favalli}

Poster Number: 0275

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

Safety of filgotinib in patients with RA: Laboratory analysis results from a long-term extension study

^{Maya Buch, James Galloway, Ennio Giulio Favalli, Arnaud Constantin, Patrick Durez, Paul Van Hoek, Christopher Watson, Pieter-Jan Stiers, Vijay Rajendran, Katrien Van Beneden, Tsutomu Takeuchi, Bernard Combe}

Poster Number: 0280

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

Clinical outcomes of filgotinib in patients with RA aged ≥65 years: A post hoc subgroup analysis of phase 2 and 3 clinical trials and ongoing long-term extensions

^{Maya Buch, Bernard Combe, Jose A. Gómez-Puerta, Roberto Caporali, Jacques-Eric Gottenberg, Paul Van Hoek, Vijay Rajendran, Pieter-Jan Stiers, Katrien Van Beneden, Daniel Aletaha, Gerd Burmester, René Westhovens, Yoshiya Tanaka}

Poster Number: 0281

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

An update on the integrated safety analysis of filgotinib in patients with moderately to severely active RA

^{Kevin Winthrop, Daniel Aletaha, Roberto F. Caporali, Yoshiya Tanaka, Tsutomu Takeuchi, Paul Van Hoek, Chris Watson, Pieter-Jan Stiers, Vijay Rajendran, Katrien Van Beneden, Jacques-Eric Gottenberg, Gerd R. Burmester}

Poster Number: 0273

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

The use of exposure-adjusted event rates versus exposure-adjusted incidence rates in adverse event reporting: Insights from filgotinib integrated safety data in RA (EULAR 2022 encore)

^{Patrick Durez, Eugen Feist, Ricardo Blanco, Vijay Rajendran, Nadia Verbruggen, Katrien Van Beneden, James Galloway}

Poster Number: 0278

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I

Effect of filgotinib on body weight and BMI and effect of baseline BMI on the efficacy and safety of filgotinib in RA (EULAR 2022 encore)

^{Alejandro Balsa, Siegfried Wassenberg, Anne Tournadre, Hans-Dieter Orzechowski, Katrien Van Beneden, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, Patrick Verschueren}

Poster Number: 0279

Session Date: 12 November, 2022
Session Time: 1:00 PM to 3:00 PM
Session: RA – Treatment poster I